JPI Conference Dublin Plenary Session Philippe Amouyel
-
Upload
jpndresearch -
Category
Health & Medicine
-
view
1.061 -
download
2
description
Transcript of JPI Conference Dublin Plenary Session Philippe Amouyel
Joint Programming Initiative on Neurodegenerative Diseases: The Next Challenges
Prof. Philippe AmouyelChair, JPND Management Board
Joint Programming as a response to societal challenges
Alzheimer’s and Neurodegenerative Diseases in Europe
Number of cases Societal costs (€)
2010 6,000,000 72,000,000,000
2040 12,000,000 144,000,000,000
A major societal challenge for the
coming years
Alzheimer’s
The JPND goals
To tackle the challenge of Alzheimer’s and other neurodegenerative diseases*, the goals of the JPND Research Strategy are:
* Alzheimer’s disease and other dementias (AD), Parkinson’s disease (PD) and PD-related disorders, Prion disease, motor neurone diseases (MND), Huntington’s disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)
• To develop new treatments and preventive strategies
• To improve health and social care approaches
• To raise awareness and de-stigmatise neurodegenerative disorders
• To alleviate the economic and social burden of these diseases
JPND Mapping 2011
from www.jpnd.eu
JPND - Clearing Steps
• The Foundations
• Agree on a Common Vision
• Build Trust
• Define Terms of Reference
• Structure the Governance
• Working Together
• The Strategic Research Agenda
• The Implementation
• Towards Sustainability
Governance
27 countries
ManagementBoard
ExecutiveBoard
Scientific Advisory
Board
JumpaheadSteering
Committee
WP2WP1 WP3 WP4 WP5
JPND Research Strategy (SRA)
• What is it?• A holistic ‘roadmap’ for future EU-wide activity and investment
• Not a review of the field, not a list of calls for proposals
• Launched Feb 7th, 2012• 5 research priorities, 9 enabling activities
• Delivery has taken into account• SAB recommendations
• Outputs from 4 scientific/strategic workshops• National and European portfolios
• Mapping exercise of National and European programmes• Broad consultation with stakeholder groups
• Both Online and Offline
A European Challenge
“The answers to these challenges will be found in science and research. This Research Strategy comes not a moment too soon. It provides a much-needed framework for European-level coordination and investment in neurodegenerative disease research.”
Mrs Máire Geoghegan-Quinn EuropeanCommissioner for Research, Innovation and ScienceLaunch of the Research Strategy of JPNDBrussels, 7 February 2012
Next Steps
• The JPI must have clear and quantifiable scientific objectives to propose• The SRA alone is not sufficient• It is only a holistic roadmap• An implementation plan is compulsory
• Objectives must be in-line with the scientific strategy of each country • Some countries have their own National Plan• Others need to build one
The Implementation Plan
• Create list of priorities from JPND Research Strategy proposals
• Organise thematic working groups
• Create list of opportunities suited for implementation
• Organise specific task forces
• Stimulate and align National Plans
• Set action groups for specific priorities and encouraging collaborations
• Support implementation
Some achievements
• Creation of stable management structure with efficient procedures
• Mapping exercise and associated public database
• JPND Joint Transnational Calls:
• One in 2011 for €15M ; Two in 2012-2013 for €25M
• Centres of Excellence in Neurodegeneration program:
• 2011 for €6M ; in 2012-13 for €8M
• Opening up to Third Countries:
• Canada already, on-going discussions with US
The next Challenges
• To implement over time
• To partner with EU
• To partner with industry
• To ensure JPND sustainability
To implement over time
• Developing attractive programs
• Easier when a National Plan already exists
• Always « a la carte »
• Need for synchronisation of funding decisions in each country (yearly basis)
• Strengthing decisions by signing Memorandum of Understanding
• Importance of phasing and overlap
• Diversity of the tools
To partner with EU
• Establish a programme of co-investment
• Work towards a sustained increased of the investment amongst JPND partners
• Leverage the value of investments and resources at both national and European Commission level, to the benefit of Europe
Examples:•Synergy between JPND actions and H2020 programme•Linking national plans through actions engaging national infrastructures•Development and long term sustainability of European cohorts•Unlocking national capability on fellowship program
To partner with Industry
• Participation in the Research Strategy delivery
• Enlarge the contacts (pharma, device, IT, diagnosis, imaging, welfare technologies, AAL, …)
• Ongoing discussions with IMI
• Not a single mechanism to interact for companies• access to infrastructures and clinical networks• associate in JPND calls• set up an educational program
To ensure JPND sustainability
• JPND is supported by the CA Jumpahead
• Improve / achieve efficiency
• Provide points of influence of key stakeholders
• Inclusive of member states interest
• Permanent full time senior management resources
• Cash / in-kind contributions from member states
• Legal structure
Joining forces to fight neurodegenerative diseases
‘We hope that JPND will be a successful pilot for research into other challenges, as well as lead to a reduction in the burden of neurodegenerative diseases.’
www.thelancet.com/neurology Vol 12 February 2013, Editorial p119
Keep up to date
• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu
• Search our Mapping Database
• Sign up to the JPND News Feeds
• E-mail us: [email protected]
• Follow us on Twitter: @JPNDEurope